PMID- 38023216
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231201
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 13
DP  - 2023
TI  - Efficacy and safety of immune checkpoint inhibitors plus recombinant human 
      endostatin therapy as second-line treatment in advanced non-small-cell lung 
      cancer with negative driver gene: a pilot study.
PG  - 1210267
LID - 10.3389/fonc.2023.1210267 [doi]
LID - 1210267
AB  - BACKGROUND: Immune checkpoint inhibitors (ICIs) have become the standard 
      second-line treatment for advanced non-small cell lung cancer (NSCLC). 
      Recent findings indicating an intertwined regulation of vascular endothelial 
      growth factor (VEGF) signaling and immunosuppression in the tumor 
      microenvironment suggest that the combination of ICIs and angiogenesis inhibitors 
      could have synergistic antitumor activity, along with favorable tolerability. 
      However, ICIs plus anti-angiogenesis therapy has not been widely evaluated. The 
      purpose of this pilot study was to evaluate the efficacy and safety of ICIs plus 
      recombinant human (rh)-endostatin as second-line treatment in advanced NSCLC with 
      negative driver gene. METHOD: Prospectively evaluated the efficacy and safety of 
      ICIs plus rh-endostain as second-line treatment in advanced NSCLC with negative 
      driver gene. The primary endpoints of the study were progression-free survival 
      (PFS) and overall survival (OS). The secondary endpoints were objective response 
      rate (ORR), disease control rate (ORR), and safety. RESULTS: A total of 34 
      patients were recruited in this study. 18 patients received ICIs plus 
      anti-angiogenesis therapy (ICIs combination therapy), and 16 patients received 
      ICIs monotherapy. DCR was 88.9% vs 43.8% (P = 0.009). Median PFS (mPFS) was 8.3 
      months vs. 3.7 months (HR = 0.276, 95% CI 0.125-0.607, P = 0.001). Median OS 
      (mOS) was 18.0 months vs 9.6 months (HR=0.364, 95% CI 0.147-0.902, P=0.009). In 
      multivariate Cox regression analysis, ICI combination therapy prolonged PFS (HR = 
      0.069, 95% CI 0.019-0.185, P < 0.001) and OS (HR = 0.044, 95% CI 0.011-0.185, P < 
      0.001). We did not observe a significant difference in the incidence of adverse 
      events (AEs) between the two groups (P > 0.05). CONCLUSIONS: Compared with ICIs 
      monotherapy, ICIs combination therapy improves clinical response in patients with 
      advanced NSCLC with negative driver gene, significantly prolongs PFS and OS, and 
      does not significantly difference the incidence of AEs.
CI  - Copyright (c) 2023 Yang, Li, Deng, Yang and Sun.
FAU - Yang, Bo
AU  - Yang B
AD  - Department of Oncology, The Third Affiliated Hospital of Anhui Medical University 
      (The First People's Hospital of Hefei), Hefei, Anhui, China.
FAU - Li, Yuzhi
AU  - Li Y
AD  - Department of Oncology, The Third Affiliated Hospital of Anhui Medical University 
      (The First People's Hospital of Hefei), Hefei, Anhui, China.
FAU - Deng, Jie
AU  - Deng J
AD  - Department of Oncology, The Third Affiliated Hospital of Anhui Medical University 
      (The First People's Hospital of Hefei), Hefei, Anhui, China.
FAU - Yang, Hui
AU  - Yang H
AD  - Department of Oncology, The Third Affiliated Hospital of Anhui Medical University 
      (The First People's Hospital of Hefei), Hefei, Anhui, China.
FAU - Sun, Xiang
AU  - Sun X
AD  - Department of Oncology, The Third Affiliated Hospital of Anhui Medical University 
      (The First People's Hospital of Hefei), Hefei, Anhui, China.
LA  - eng
PT  - Journal Article
DEP - 20231107
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC10661927
OTO - NOTNLM
OT  - anti-angiogenesis
OT  - immune checkpoint inhibitors
OT  - non-small cell lung cancer
OT  - recombinant human endostatin
OT  - second-line
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/11/29 18:42
MHDA- 2023/11/29 18:43
PMCR- 2023/01/01
CRDT- 2023/11/29 15:42
PHST- 2023/04/22 00:00 [received]
PHST- 2023/10/19 00:00 [accepted]
PHST- 2023/11/29 18:43 [medline]
PHST- 2023/11/29 18:42 [pubmed]
PHST- 2023/11/29 15:42 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2023.1210267 [doi]
PST - epublish
SO  - Front Oncol. 2023 Nov 7;13:1210267. doi: 10.3389/fonc.2023.1210267. eCollection 
      2023.